evipedia.ai
← Back

5-MeO-DMT for Health & Longevity

Evidence Review created on 09/06/2026 using AI4L / Opus 5

Also known as: 5-methoxy-N,N-dimethyltryptamine, Mebufotenin, O-methylbufotenin, Bufo, Toad Venom, GH001, BPL-003

Motivation

5-MeO-DMT — short for 5-methoxy-N,N-dimethyltryptamine, and also called mebufotenin — is a compound found in the venom of the Sonoran Desert toad and in a number of South American plants, and it is now made synthetically for medical research. Inhaled, vaporized or sprayed into the nose, it produces an extremely brief but overwhelming altered state, usually lasting well under an hour, in which the ordinary sense of a separate self falls away entirely.

Plants carrying the compound have been used in ritual snuffs for centuries, and inhaling dried toad secretion spread through underground retreat circles from the 1980s onward. Attention turned clinical when hospital trials began reporting that a single day of dosing appeared to lift severe, long-standing depression within hours rather than the weeks conventional treatment usually needs. Two companies now carry it through clinical development.

This review sets out what is currently known about 5-MeO-DMT through a health and longevity lens: how it acts on the brain and body, what the trial and real-world evidence shows for mood, drinking behavior and general wellbeing, what harms have been recorded, and how preparation, setting and legal status shape the picture.

Benefits - Risks - Protocol - Conclusion

High-level overviews of 5-MeO-DMT from expert platforms and from narrative scientific literature, selected to cover both the therapeutic case and the skeptical case.

Note on priority platforms: only four sources clear the depth bar, so four are listed rather than five. Peter Attia, Life Extension Magazine and Lifespan.io have published nothing on 5-MeO-DMT; Chris Kresser’s only coverage is two passing sentences in a general psychedelic-therapy episode; and Rhonda Patrick’s FoundMyFitness carries only a short news digest of one veterans study. The list has not been padded to reach five.

Grokipedia

  • 5-MeO-DMT

    A dedicated encyclopedia entry covering the compound’s chemistry, natural sources, receptor pharmacology, legal scheduling and clinical development, with inline citations that make its factual claims traceable.

Examine

Examine has no dedicated 5-MeO-DMT article. Its only 5-MeO-DMT content is a members-only research-feed summary of a single depression trial, which is a research-feed entry rather than the site’s primary, dedicated page for an intervention.

5-MeO-DMT is a controlled, investigational medicine rather than a dietary supplement, and Examine’s coverage is built around supplements and nutrition, which explains the absence of an entry.

ConsumerLab

ConsumerLab has no 5-MeO-DMT article, review or clinical update.

ConsumerLab tests commercially sold dietary supplements. 5-MeO-DMT is a controlled, investigational medicine that cannot legally be sold as a supplement, so it falls outside the organization’s testing scope.

Systematic Reviews

Systematic reviews and meta-analyses covering 5-MeO-DMT, spanning both the claimed benefit — symptom and substance-use reduction — and the principal risks of adverse events, drug interactions and unmapped pharmacokinetics.

Mechanism of Action

5-MeO-DMT is a tryptamine that activates serotonin receptors with an unusual preference. Its affinity for the 5-HT1A receptor (a calming serotonin docking site dense in the brainstem and cortex) is roughly an order of magnitude higher than for the 5-HT2A receptor (the excitatory serotonin docking site that drives classic psychedelic effects). Most classic psychedelics show the reverse pattern.

Selectivity and tissue distribution. The molecule is small and fat-soluble, crosses from lung or nasal mucosa into the brain within seconds, and also binds serotonin transporters and, weakly, several other monoamine receptors.

Metabolism. The dominant route is breakdown by monoamine oxidase A (MAO-A, the enzyme that clears serotonin and related amines). A secondary route runs through CYP2D6 (a liver enzyme whose activity varies widely between individuals) and yields bufotenine, which is itself psychoactive.

Half-life. After inhalation the plasma half-life (the time for blood levels to halve) is roughly 10–20 minutes, among the shortest of any psychedelic. Subjective effects peak at 8–15 minutes and resolve within an hour.

Competing explanations. One account attributes benefit to 5-HT2A-driven cortical rewiring, mirroring psilocybin. A second attributes it to 5-HT1A-mediated quieting of emotion-processing and self-referential circuits, which would make the compound mechanistically distinct from other psychedelics. A third proposes that it triggers brief seizure-like cortical activity, placing it closer to electroconvulsive therapy. None has been tested against the others in humans.

Historical Context & Evolution

5-MeO-DMT was first synthesized in 1936, before anyone knew it occurred in nature, and was isolated from the plant Dictyoloma incanescens in 1959. It is a major constituent of Anadenanthera seed snuffs — yopo and cebil — prepared and inhaled as snuff across South America and the Caribbean for centuries, and it occurs in Virola and Phalaris species as well. Its original role was therefore ritual and divinatory rather than medical.

In 1965 Italian pharmacologist Vittorio Erspamer identified it in the gland secretion of the Sonoran Desert toad, Incilius alvarius, at concentrations far above anything found in plants. Analytical work has since put the mean content of dried secretion at about 410,000 µg/g, alongside variable bufotenine (Schwelm et al., 2022). A 1984 self-published pamphlet describing how to collect and vaporize the secretion moved the practice out of the desert and into an underground ceremonial circuit.

The shift toward health optimization came from survey work. A 515-respondent study found infrequent, mostly spiritual use, low craving, and self-reported symptom improvement across several psychiatric diagnoses (Davis et al., 2018). That signal, rather than any laboratory finding, prompted commercial development. What changed after 2019 was not that older reports were overturned but that uncontrolled self-report was replaced by dose-controlled trials — which have so far pointed the same way while introducing new questions about masking and durability.

Expected Benefits

Two commercial sponsors — GH Research (inhaled GH001) and Beckley Psytech, now part of atai (intranasal BPL-003) — own the formulations used in almost every trial cited below and have a direct financial interest in a positive result. This conflict of interest applies to the whole benefit evidence base and should be read into every item.

High 🟩 🟩 🟩

Rapid Remission of Treatment-Resistant Depressive Symptoms

Repeated dosing within a single day produces symptom collapse on the Montgomery-Åsberg Depression Rating Scale (MADRS, a clinician-rated 0–60 depression severity score) within hours, not weeks. The finding now rests on a randomized, placebo-controlled phase 2b trial of inhaled 5-MeO-DMT (Cubala et al., 2026), an earlier phase 1/2 dose-escalation trial (Reckweg et al., 2023), an open-label intranasal trial (Roberts et al., 2026) and an open-label postpartum trial (Johnson et al., 2026). All were sponsor-run, small, and impossible to mask convincingly.

Magnitude: In the 81-patient placebo-controlled trial, depression scores fell 15.5 points further than placebo by day 8 (effect size −2.0), with 57.5% versus 0% meeting the remission threshold.

Medium 🟩 🟩

Reduced Alcohol Consumption and Craving

A single intranasal dose given inside a ten-week course of cognitive behavioral therapy was followed by large reductions in drinking sustained to twelve weeks (Marsden et al., 2025). A meta-analysis of dimethyltryptamine-class agents found the effect on substance use was roughly twice as large when psychotherapy accompanied dosing, which makes attribution to the drug alone impossible (Wallace et al., 2026). The trial was open-label, uncontrolled, sponsor-run and enrolled thirteen people.

Magnitude: Across twelve completers, abstinent days rose from 33.2% to 80.8% and heavy-drinking days fell from 56.2% to 13.2% by week 12; half were continuously abstinent.

Reduced Anxiety and Stress Symptoms

Prospective field studies using validated depression, anxiety and stress scales recorded falls in anxiety and stress ratings that reached significance at four weeks after a single inhalation (Uthaug et al., 2019), replicated in a smaller synthetic-compound cohort (Uthaug et al., 2020) and echoed by 79% of survey respondents with a prior anxiety diagnosis (Davis et al., 2019). No controlled trial has used anxiety as a primary endpoint. Participants were self-selected retreat attendees, an unusually motivated group.

Magnitude: Anxiety and stress ratings fell from baseline and remained lower at four weeks, with the largest drops in those reporting complete ego dissolution; the literature reports no controlled outcome figure for anxiety as a primary endpoint.

This is the benefit most directly relevant to a non-clinical, optimization-oriented reader. Satisfaction with life, convergent thinking and mindfulness-related capacities rose after a single inhalation and were still elevated four weeks later (Uthaug et al., 2019); non-judgmental awareness rose in a synthetic-compound cohort (Uthaug et al., 2020); and automated speech analysis around a retreat showed a durable shift from outward focus toward introspection (Kuc et al., 2026). All three are uncontrolled observational cohorts of retreat participants.

Magnitude: Life-satisfaction and mindfulness ratings rose immediately after dosing and remained above baseline at four weeks in a 42-person prospective cohort; the published reports give no standardized outcome figure.

Low 🟩

Reduction in Post-Traumatic Stress Symptoms

A retrospective survey of special operations veterans reported very large falls in post-traumatic stress, depression and suicidal thinking (Davis et al., 2020). A single longitudinal case adds detail (Ragnhildstveit et al., 2023). Every participant also received ibogaine, so the design cannot separate the two compounds.

Magnitude: Retrospective before-and-after scores in 51 veterans showed a very large drop in post-traumatic stress symptoms (Cohen’s d = −3.6, a standardised effect size on which 0.8 already counts as large); because ibogaine was co-administered, no figure is attributable to 5-MeO-DMT alone.

Speculative 🟨

Cortical Structural Plasticity

A single dose raised dendritic spine density in mouse frontal cortex for weeks and altered plasticity-related genes in stressed mice (Jefferson et al., 2023). The basis is animal work only; no human structural data exist.

Anti-Inflammatory and Neuroendocrine Signaling

Salivary interleukin-6 (IL-6, a protein driving inflammation) fell and cortisol rose after inhalation in eleven uncontrolled volunteers (Uthaug et al., 2020). The remaining basis is mechanistic and preclinical only (Low et al., 2025).

Benefit-Modifying Factors

  • CYP2D6 metabolizer status: Poor metabolizers of this liver enzyme clear the parallel pathway to bufotenine more slowly, which animal pharmacokinetic work suggests raises and prolongs exposure (Shen et al., 2010). No human genotype-stratified efficacy data exist.

  • Baseline symptom severity: Trial entrants carried mean depression scores near 33–37 out of 60. Benefit magnitude has only been demonstrated from a severe baseline, and regression toward the mean inflates apparent gains most in the sickest participants.

  • Baseline inflammatory markers: Preclinical work indicates psychedelics reduce inflammatory signaling mainly where inflammation is already elevated and may raise it under normal conditions (Low et al., 2025), so a low-inflammation baseline may leave little to gain.

  • Depth of the acute experience: Across survey and field studies, people reporting complete ego dissolution or oceanic boundlessness show the largest and most durable mood gains (Uthaug et al., 2019). Sub-threshold dosing has not reproduced the effect.

  • Sex: Rodent studies show sex-dependent differences in behavioral and neuroimaging responses to 5-MeO-DMT (Marecki et al., 2026). Human trials enrolled 54–60% women but published no sex-stratified efficacy analysis.

  • Pre-existing health conditions: Efficacy has been shown only in treatment-resistant depression, postpartum depression and alcohol use disorder. Healthy-volunteer trials measured tolerability and phenomenology, not benefit, so gains in an already-well person are unmeasured.

  • Age: Trials capped enrollment at 64 or 75 years and enrolled participants averaging 40–49. Nothing is known about response above 75, where cardiovascular reserve and drug clearance both decline.

  • Preparation and integration support: Every clinical result was produced with structured pre-dose preparation and post-dose integration sessions. The meta-analytic substance-use effect roughly doubled when psychotherapy was included (Wallace et al., 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

Transient Cardiovascular Activation

Blood pressure and heart rate rise sharply during the acute effect and settle within the observation window. This is the most consistently reported physiological event across the sponsor-run programs, appearing in the intranasal alcohol trial (Marsden et al., 2025), the intranasal depression trial (Roberts et al., 2026) and the inhaled trials. Trial protocols exclude uncontrolled hypertension and clinically significant electrocardiogram findings, so the observed rate understates risk in an unscreened population.

Magnitude: Transient blood-pressure elevations affected 4 of 13 participants (30.8%) in the alcohol trial; one of twelve in the intranasal depression trial had a severe elevation that returned to baseline before discharge.

Nausea, Vomiting, and Headache

Gastrointestinal upset and headache are the most frequent treatment-related events across every published trial and are also near-universal in retreat settings, where purging is often framed as part of the process. The mechanism is direct serotonin-receptor stimulation of gut and vascular tissue. Events are short-lived and self-resolving, including at sub-psychedelic sublingual doses (Bistue Millón et al., 2025) and in the postpartum trial (Johnson et al., 2026).

Magnitude: Nausea and nasal discomfort were the two most frequent treatment-related events in the intranasal depression trial (18 events across 9 of 12 participants, 75.0%); headache was the most frequent event in the inhaled postpartum trial.

Acute Fear, Anxiety, and Loss of Behavioral Control

Onset is near-instantaneous and the loss of self-reference is total, so there is no window in which a person can moderate the experience. Microphenomenology interviews in psychedelic-naive volunteers describe strong emotional and bodily upheaval with little visual content (Ermakova et al., 2025); naturalistic electroencephalography work documents complete absence of self-experience in extreme cases (Timmermann et al., 2025). Trials manage this with a trained sitter throughout.

Magnitude: In a 515-respondent survey an average of 37% reported challenging effects such as anxiousness or fear, at a mean intensity of 0.95 on a 0–5 scale (Davis et al., 2018).

Nasal Irritation and Administration-Site Pain

Specific to the intranasal powder formulation. Local mucosal irritation and administration-site pain were among the most common events in both intranasal trials (Marsden et al., 2025) and the protocol for the larger dose-finding trial excludes anyone with nasal obstruction or congestion at dosing. It is a formulation-specific nuisance rather than a systemic hazard, and it does not apply to inhaled or intramuscular routes.

Magnitude: Administration-site pain affected 4 of 13 participants (30.8%) in the alcohol trial, and nasal discomfort was one of the two most frequently reported events in the intranasal depression trial.

Medium 🟥 🟥

Reactivations (Spontaneous Re-Experiencing) ⚠️ Conflicted

Days to months after dosing, the drug state can return unbidden, without re-administration. Survey work in Spanish-speaking respondents put prevalence at 69%, with 97% of those episodes rated positive or neutral and longer preparation predicting their occurrence (Ortiz Bernal et al., 2025), replicating an earlier analysis (Ortiz Bernal et al., 2022). Clinical trials, by contrast, record them as treatment-emergent adverse events. Net reading: reactivations are common and usually experienced as neutral or welcome, but they are unpredictable and a minority are distressing.

Magnitude: 69% of a 90-respondent survey sample reported reactivations, 97% of them positive or neutral; 2 of 13 participants (15.4%) in the alcohol trial reported them as adverse events.

Low 🟥

Serotonin Toxicity When Combined with Monoamine Oxidase Inhibitors

MAO-A is the main clearance route, so blocking it multiplies exposure. A man died after drinking a plant preparation containing 5-MeO-DMT and harmala alkaloids, with no anatomical cause at autopsy (Sklerov et al., 2005). Animal work confirms large exposure increases when the enzyme is inhibited (Jiang et al., 2013).

Magnitude: One published death involved a heart-blood concentration of 1.88 mg/L alongside harmala alkaloids; no controlled human interaction study exists, so the literature reports no incidence figure.

Psychiatric Destabilization in Predisposed Individuals

Every trial excludes personal or family history of schizophrenia, bipolar disorder or psychotic depression, so the compound’s own risk here is unmeasured. Across the wider psychedelic literature, serious events including psychosis, mania and suicidal behavior cluster entirely in participants with pre-existing illness (Hinkle et al., 2024).

Magnitude: Across 214 classic-psychedelic studies, serious adverse events affected roughly 4% of participants with pre-existing neuropsychiatric disorders and none of the healthy participants.

Physical Injury During the Acutely Incapacitated State

For roughly fifteen to twenty minutes the person is unresponsive to instruction and cannot protect an airway. Trials eliminate this by dosing supine with a sitter; community harm-reduction guidance identifies unsupervised use as the dominant preventable hazard (Kruger et al., 2025). Injury reports come from community sources, not a register.

Magnitude: Not quantified in available studies. Trials dose participants supine under continuous observation and record no injuries, so no controlled setting has generated a denominator for unsupervised use.

Speculative 🟨

Seizure-Like Cortical Activity

A review argues the acute state and reactivations resemble temporal-lobe epileptiform activity (Dourron et al., 2025). A canine electroencephalography study found no seizures (Lotfi et al., 2026). The basis is hypothesis and animal work only.

Cardiotoxicity and Contaminants from Toad-Derived Secretion

Dried Incilius alvarius secretion contains variable bufotenine plus heart-active bufadienolides absent from purified drug (Schwelm et al., 2022, Luccioni et al., 2025). The basis is analytical and veterinary only; no human outcome study exists.

Risk-Modifying Factors

  • CYP2D6 genotype: Poor metabolizers of this liver enzyme show higher and longer 5-MeO-DMT exposure in animal models, particularly when an enzyme inhibitor is also present (Shen et al., 2010), plausibly raising cardiovascular and psychological event risk.

  • Baseline blood pressure and electrocardiogram: Every trial screened out uncontrolled hypertension and clinically significant electrocardiogram abnormalities. An elevated baseline or a prolonged electrical recovery interval converts the transient pressor response (the sharp blood-pressure rise during dosing) into a hazard.

  • Baseline inflammatory and hepatic markers: No trial has linked baseline laboratory values to adverse events, but impaired liver function slows both clearance routes, and no dose adjustment for hepatic impairment has been established.

  • Sex: Rodent work shows sex-dependent differences in dose-response and brain connectivity (Marecki et al., 2026). Human safety data are not sex-stratified. Pregnancy and lactation were exclusion criteria in every trial.

  • Pre-existing psychiatric conditions: Personal or first-degree family history of schizophrenia, bipolar disorder, psychotic depression or delusional disorder, current personality disorder, and recent suicidal ideation were all exclusion criteria, and serious events concentrate in psychiatric populations.

  • Pre-existing cardiac and seizure conditions: Trials excluded any seizure within two years and uncontrolled cardiac disease. The transient pressor response and the disputed epileptiform hypothesis both bear directly on these groups.

  • Age: Enrollment ceilings of 64 and 75 years mean older adults are unstudied. Weaker automatic blood-pressure control and reduced liver clearance would both be expected to amplify the cardiovascular response.

  • Concurrent serotonergic medication: Serotonin reuptake inhibitors, monoamine oxidase inhibitors and harmala-containing preparations all alter serotonin handling. One trial continued reuptake inhibitors without incident (Seynaeve et al., 2026); enzyme inhibitors are a different matter.

Key Interactions & Contraindications

  • Monoamine oxidase inhibitors — prescription (phenelzine, tranylcypromine, isocarboxazid, selegiline, moclobemide): Absolute contraindication. Blocking the main clearance enzyme multiplies exposure and risks life-threatening serotonin toxicity. One published death followed co-ingestion with plant monoamine oxidase inhibitors. No safe separation interval has been established.

  • Harmala-containing preparations — over-the-counter and botanical (ayahuasca, Banisteriopsis caapi, Peganum harmala, yopo admixtures): Absolute contraindication, and the exposure that caused the recorded fatality. These are sold as supplements and are frequently combined with tryptamines in ceremonial settings.

  • Serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine): Caution. Additive serotonergic load with theoretical serotonin toxicity risk; also blunted subjective effects. A proof-of-concept trial continued them safely under monitoring, so monitor rather than mandate withdrawal.

  • Other serotonergic prescription drugs (triptans, tramadol, linezolid, lithium): Caution with monitoring for agitation, tremor, hyperthermia and rapid heart rate. Protocols separate dosing where possible and avoid initiating any new serotonergic agent in the week around a session.

  • CYP2D6 inhibitors — prescription (paroxetine, fluoxetine, bupropion, quinidine, terbinafine): Monitor. Blocking the secondary clearance route raises parent-compound exposure in animal models. Practical consequence is a stronger, longer acute effect, so protocols use a reduced starting dose.

  • Antihypertensive and cardiac medication (beta-blockers, calcium channel blockers): Monitor. These do not contraindicate use but change the shape of the acute pressor response, and beta-blockade can mask the rising heart rate that signals an escalating cardiovascular event.

  • Over-the-counter serotonergic agents (dextromethorphan cough preparations, St John’s wort): Caution. Both add serotonergic tone and St John’s wort additionally induces drug-metabolizing enzymes. Consequence is unpredictable exposure plus additive toxicity risk; St John’s wort is discontinued at least two weeks beforehand.

  • Supplements with additive serotonergic effect (5-hydroxytryptophan, L-Tryptophan, S-adenosylmethionine, high-dose Rhodiola rosea extract): Caution. Each raises serotonin availability or weakly inhibits monoamine oxidase, compounding the same toxicity mechanism. Trial protocols withhold these for at least 48 hours before and after a session.

  • Supplements with additive cardiovascular effect (high-dose caffeine, synephrine, yohimbine, ephedra-type stimulants): Caution. These stack with the acute pressor response and can push systolic pressure into a range that would otherwise have been avoided. Protocols withhold these on the dosing day.

  • Other psychedelic and dissociative interventions (psilocybin, lysergic acid diethylamide, ibogaine, ketamine): Caution. Ibogaine in particular prolongs the heart’s electrical recovery time, and the veterans data that motivate combined use came from sequential same-program dosing, an untested pairing outside that setting.

Populations who should avoid 5-MeO-DMT:

  • Personal history of schizophrenia, schizoaffective disorder, delusional disorder, bipolar I or II disorder, or psychotic depression
  • First-degree relative with schizophrenia, bipolar disorder, delusional disorder or schizoaffective disorder
  • Suicidal ideation, suicide attempt or self-injurious behavior within the previous 12 months
  • Uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg on repeated seated measurement)
  • Coronary artery disease, recent myocardial infarction (<6 months), decompensated heart failure (New York Heart Association Class III–IV), or corrected QT interval (a measure of the heart’s electrical recovery time) >500 ms
  • Any seizure within the previous 2 years, or a diagnosed seizure disorder
  • Current use of a monoamine oxidase inhibitor or any harmala-containing preparation
  • Pregnancy, planned pregnancy, or lactation
  • Moderate to severe hepatic impairment (Child-Pugh Class B or C)
  • Current alcohol or substance use disorder outside a supervised treatment program

Risk Mitigation Strategies

  • Individualized dose escalation: Starting at 6 mg and escalating to 12 mg and 18 mg in one day, stopping once a peak experience occurs, produced higher remission than fixed dosing and limits needless cardiovascular and fear exposure.

  • Cardiovascular screening before exposure: Seated blood pressure twice plus a 12-lead electrocardiogram, excluding systolic ≥160 mmHg, diastolic ≥100 mmHg or corrected QT interval >500 ms, addresses the transient pressor response — the most consistent physiological adverse event.

  • Continuous monitoring to discharge readiness: Blood pressure and heart rate every 15 minutes for the first hour, discharging only after a readiness assessment; median time in trials was 98 minutes (Roberts et al., 2026). This catches severe pressor responses.

  • A trained sitter and supine dosing: One or two trained monitors present throughout, with the person lying down and the airway observable, eliminates falls, aspiration and injury during the 15–20 minutes of unresponsiveness.

  • A four-week serotonergic washout audit: Protocols screen for monoamine oxidase inhibitors, harmala preparations, St John’s wort, 5-hydroxytryptophan and tramadol, discontinuing each at an appropriate interval. This addresses the single mechanism behind the only recorded fatality.

  • Purified, assayed material rather than toad secretion: Using a synthesized salt with a certificate of analysis removes the bufadienolide and variable-bufotenine hazard entirely and makes dose escalation arithmetically meaningful.

  • Structured preparation and integration sessions: Three pre-dose and three post-dose sessions were used in the alcohol trial. These address prolonged distress and give a channel for handling reactivations, which affect a majority of people at some point.

  • Advance briefing on reactivations: Explaining before dosing that the state can return unbidden for weeks to months converts an alarming event into an anticipated one, and is the practical countermeasure to the most common delayed effect.

Therapeutic Protocol

  • Individualized escalating inhalation (GH Research): Up to three vaporized doses of 6, 12 and 18 mg on one day, each given only if the previous dose produced no peak experience. This regimen carried the phase 2b result.

  • Fixed single intranasal dose (Beckley Psytech protocol): One 10 mg or 12 mg intranasal dose of the benzoate salt powder, with psychological support before, during and after. Simpler to deliver but produced smaller symptom changes than escalating inhalation.

  • Traditional inhaled toad secretion (Sonoran lineage, from 1984): Roughly 30–50 mg of dried secretion vaporized in one breath, about 12–20 mg of active compound but unassayed. Now largely displaced by synthetic material for conservation and safety.

  • Sub-psychedelic sublingual dosing (Biomind Labs protocol): Weekly sublingual doses of 6, 9 or 12 mg produced measurable brain-activity changes without a full psychedelic state and were well tolerated over four weeks (Bistue Millón et al., 2025). Efficacy remains unproven.

  • Best time of day: Morning dosing is standard across all trial protocols. It allows the full observation period, discharge readiness assessment and same-day integration contact within working hours, and leaves the evening free of residual activation.

  • Half-life and session duration: The plasma half-life after inhalation is roughly 10–20 minutes and subjective effects resolve within an hour, which is why sessions run 2–3 hours rather than the 6–8 hours psilocybin protocols require.

  • Single versus split dosing: Escalating same-day doses outperformed a single dose, with 87.5% remission versus 25–50% (Reckweg et al., 2023). Splitting across separate days has not been studied.

  • Preparation and integration schedule: Three preparation sessions before dosing and three integration sessions afterwards, ahead of any structured therapy, is the pattern used in the alcohol trial and is the design feature most associated with larger effects.

  • CYP2D6 and pharmacogenetic considerations: Poor metabolizer status raises exposure in animal models, arguing for the lowest escalation step. No trial has genotyped participants, and APOE4 (fat transport), MTHFR (folate processing) and COMT (dopamine breakdown) remain unexamined.

  • Sex-based differences: Rodent studies show sex-dependent dose-response and connectivity differences (Marecki et al., 2026). Human protocols use identical doses for men and women, and no trial has published a sex-stratified dose analysis.

  • Age considerations: Trial ceilings were 64 and 75 years. For anyone at the upper end of that range, the conservative approach is the lowest escalation step with extended cardiovascular monitoring, since no data exist above 75.

  • Baseline biomarkers and pre-existing conditions: Protocols require controlled blood pressure, an unremarkable electrocardiogram, no uncontrolled thyroid, renal or metabolic disease, and no recent suicidality. Depression severity of at least moderate intensity was an entry requirement in every efficacy trial.

Discontinuation & Cycling

  • Not a chronic medication: Every protocol studied to date is a one-day or two-dose intervention followed by months of observation, not ongoing administration. There is no maintenance regimen to discontinue and no established dosing interval.

  • No withdrawal syndrome identified: Survey data show very low craving (8% of 515 respondents) and no dependence (Davis et al., 2018), and no trial has recorded withdrawal after single or repeat dosing. The pharmacology gives no obvious dependence mechanism.

  • Tapering is not applicable: Because exposure is a single session rather than steady-state dosing, there is nothing to taper. What does require a taper is any serotonergic medication withdrawn beforehand, which should follow that drug’s own schedule.

  • Rapid tolerance within a session: Escalating same-day doses work because tolerance builds fast; 39% of survey respondents redosed in one session (Davis et al., 2018), and redosing is not a route to a stronger effect.

  • Redosing intervals are unestablished: The larger dose-finding trial offered a second dose after eight weeks, and its open-label extension is still testing this. No evidence supports scheduled cycling, and durability beyond six months is unmeasured.

  • Relapse rather than rebound: Where benefit fades, published follow-up describes gradual return of baseline symptoms rather than a rebound below baseline. Interpreting this is difficult because no trial has followed an untreated comparison group past eight weeks.

Sourcing and Quality

  • Synthetic salt over toad secretion: Pharmaceutical-grade material is prepared as a defined salt — succinate for research use (Sherwood et al., 2020), benzoate for the intranasal product — giving a known molecular weight and a stable, weighable solid. Toad secretion offers none of this.

  • Certificate of analysis and identity confirmation: What to look for is a batch certificate reporting identity by mass spectrometry and nuclear magnetic resonance, assay purity above 98%, residual solvent limits, and explicit quantification of bufotenine as a related substance.

  • Bufotenine and bufadienolide content in natural material: Dried Incilius alvarius secretion averages roughly 410,000 µg/g of 5-MeO-DMT but bufotenine varies from about 900 to 4,700 µg/g between individual animals (Schwelm et al., 2022), alongside heart-active bufadienolides.

  • Freebase versus salt form: The freebase is what vaporizes; salts are used for intranasal, sublingual and injectable routes and do not vaporize cleanly. Dose figures are not interchangeable between forms, since the salt counter-ion adds mass.

  • Storage and stability: The freebase oxidizes on exposure to light and air and should be kept cold, dark and sealed. Discoloration toward yellow or brown indicates degradation and an unknown remaining potency.

  • Legitimate supply routes: Outside a clinical trial there is no lawful supplier in the United States, the United Kingdom or most of the European Union. Compounding pharmacies cannot supply a Schedule I substance, and no reputable brand exists.

  • Cell-based and biosynthetic production: A toad-free route using cultured Incilius alvarius parotoid-gland cells has been demonstrated (Lerer et al., 2023), which addresses the conservation pressure that wild-toad harvesting places on the species.

Practical Considerations

  • Time to effect: Unusually fast. Onset is within seconds to one minute of inhalation, and antidepressant remission was observed from two hours after the final dose in trials, with the primary endpoint measured at day 8 rather than after weeks of dosing.

  • Common pitfall — treating dose as the target: Escalation protocols stop when a peak experience occurs, not at a fixed milligram figure. Pushing to a higher dose after a peak has been reached adds cardiovascular and fear risk without adding measured benefit.

  • Common pitfall — combining with plant enzyme inhibitors: The single recorded death came from oral co-ingestion with harmala alkaloids. In ceremonial settings this combination is common and is frequently not recognized as pharmacologically distinct from the inhaled route.

  • Common pitfall — dosing without a sitter: For 15–20 minutes the person cannot protect an airway or respond to instruction. Solo use converts a manageable acute state into the main preventable source of physical harm.

  • Regulatory status: 5-MeO-DMT has been Schedule I in the United States since 2011 and is controlled in most of Europe. It has no approved indication anywhere, so lawful access outside a registered clinical trial does not currently exist, and off-label prescribing is not possible.

  • Cost and payer incentives: No price exists yet, but a single-day, two-to-three-hour session contrasts with esketamine, which requires twice-weekly supervised dosing for weeks. Institutional payers therefore have a structural incentive favoring the shorter intervention, independent of comparative efficacy.

  • Accessibility: Trial sites cluster in Europe, the United Kingdom and Ireland. The main non-trial route is an unregulated retreat sector in Mexico, the Netherlands and Central America, where facilitator training, screening and emergency provision are not standardized.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. The compound produces sleep-like cortical rhythms during waking and a dissociation between vigilance states in mice (Bréant et al., 2026), and trial participants commonly report altered sleep for several nights. Nightmares affected two of thirteen participants in the alcohol trial (Marsden et al., 2025). Morning dosing limits the disturbance.

  • Nutrition: Indirect but practically important. Nausea and vomiting are near-universal, so trial protocols dose after a light meal or a short fast. Foods and supplements carrying serotonergic or monoamine oxidase-inhibiting activity — St John’s wort, 5-hydroxytryptophan, tryptophan loading — must be excluded, and heavy caffeine intake compounds the pressor response.

  • Exercise: Indirect, with no evidence of blunting or potentiation of training adaptation. The relevant consideration is timing: strenuous exercise on the dosing day stacks cardiovascular load onto the acute pressor response. Trials place no exercise restriction beyond the observation period, and no study has measured performance outcomes.

  • Stress management: Potentiating in both directions. Salivary cortisol rose after inhalation while inflammatory signaling fell (Uthaug et al., 2020), and mindfulness-related capacities rose for weeks afterwards (Uthaug et al., 2019). Existing meditation practice appears to make integration easier, and structured integration sessions are the setting in which the mood effect has been demonstrated.

Monitoring Protocol & Defining Success

Before any exposure, the purpose of baseline testing is to exclude the specific conditions that convert a transient cardiovascular and psychological surge into a hazard, and to fix a reference point for symptom change. Seated blood pressure on two separate occasions, a 12-lead electrocardiogram, liver enzymes, and validated mood and anxiety questionnaires form the minimum set, with a structured psychiatric and family history alongside a full serotonergic medication and supplement audit.

Ongoing monitoring is front-loaded rather than continuous, because exposure is a single session. Blood pressure and heart rate are recorded every 15 minutes for the first hour and again before discharge; mood and anxiety scores are repeated at day 2, day 8, week 4, week 8 and month 6; liver enzymes are rechecked at week 4 only if baseline values were abnormal. Success is a sustained fall in symptom scores without cardiovascular events.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Seated blood pressure 110–120 / 70–80 mmHg Baseline for the acute pressor response Conventional threshold for concern is ≥140/90 mmHg; two separate seated readings after five minutes of rest, arm supported
Resting heart rate 50–70 bpm Baseline for acute tachycardia and for spotting beta-blockade masking Measure before caffeine; a resting rate above 90 bpm warrants investigation before dosing
12-lead electrocardiogram, corrected QT interval <440 ms (men), <460 ms (women) Screens for repolarization delay that a serotonergic surge could aggravate Corrected QT interval is a measure of the heart’s electrical recovery time; >500 ms is an exclusion in every trial protocol
ALT 10–26 U/L Detects impaired clearance capacity in the liver ALT is alanine aminotransferase, a liver enzyme; conventional upper limits run to 40–55 U/L, well above the functional target
hs-CRP <0.5 mg/L Baseline inflammatory tone, since anti-inflammatory signaling is a proposed mechanism hs-CRP is high-sensitivity C-reactive protein, a marker of body-wide inflammation; conventional low-risk cut-off is <1.0 mg/L; repeat if recently unwell
PHQ-9 0–4 Tracks the primary outcome the intervention targets PHQ-9 is the 9-item Patient Health Questionnaire, a validated 0–27 depression scale; 5–9 is mild, ≥20 severe
GAD-7 0–4 Tracks anxiety, the second most consistently reported gain GAD-7 is the 7-item Generalized Anxiety Disorder scale, a validated 0–21 measure; 10 or above indicates clinically significant anxiety
CYP2D6 genotype No established target value; report as poor, intermediate, normal or ultrarapid metabolizer and start at the lowest escalation step if poor Predicts exposure through the secondary clearance route One-off buccal or blood test; result never changes, so it is carried forward rather than repeated

Qualitative markers worth tracking alongside laboratory values:

  • Sleep quality and dream intensity for the first fortnight, since altered sleep and nightmares are among the more common delayed effects
  • Frequency, duration and emotional tone of reactivations, recorded as they occur rather than recalled later
  • Emotional reactivity and the sense of distance from difficult thoughts, which is the change most consistently reported in field studies
  • Alcohol intake in units per week, where drinking reduction is the intended outcome
  • Cognitive clarity and energy in the first week, distinguishing genuine improvement from post-session fatigue
  • Whether the personal meaning attributed to the session holds up at four weeks or fades, since durable attribution tracks durable benefit

Emerging Research

  • Largest controlled trial to date, results still unpublished: NCT05870540 randomized 196 people with treatment-resistant depression across low, medium and high intranasal doses under quadruple masking, with an open-label extension offering a second dose, completing July 2025. No results are posted to the registry and no peer-reviewed report has appeared.

  • Longer-term open-label safety and pharmacodynamics: NCT05660642 is enrolling 72 patients with treatment-resistant depression in a phase 2 open-label study of the intranasal formulation’s safety, tolerability and pharmacodynamics, running to November 2026. It is the longest-running 5-MeO-DMT study currently recruiting.

  • First independent academic pharmacology program: NCT07444788 at University Hospital Basel will give intravenous 5-MeO-DMT to 40 healthy participants through 2028. Its value is that it is not sponsored by either formulation owner, so it can test dose-response without a commercial stake.

  • Cognitive impairment as a new indication: NCT06812221 tested sublingual 5-MeO-DMT for anxiety and depression in 20 people with mild cognitive impairment, completing February 2025. A negative or null result here would narrow the plausible therapeutic range considerably.

  • Which mechanism is doing the work: Mouse dendritic spine findings (Jefferson et al., 2023) support a plasticity account, while the epileptiform hypothesis (Dourron et al., 2025) predicts a very different safety profile. Human electroencephalography during dosing is the discriminating experiment.

  • Whether masking failure inflates the effect: The placebo arm of the phase 2b trial produced zero remissions (Cubala et al., 2026), which argues against pure expectancy, but every participant knew which arm they were in. Active-comparator designs would settle this and none is registered.

  • Non-profit and non-commercial development: Usona Institute, a non-profit medicines developer that would not sell the product, has completed an intramuscular pharmacokinetic study (NCT05698095) in 54 volunteers. Its findings carry no revenue incentive, unlike those of the two commercial sponsors.

  • Inflammation and brain injury as adjacent targets: A preclinical systematic review of psychedelic immunomodulation (Low et al., 2025) and a review of traumatic brain injury applications (Plummer et al., 2025) map where a longevity-relevant case might eventually be built. Neither rests on human outcome data.

Conclusion

5-MeO-DMT is a short-acting compound from toad venom and certain plants that, for a few minutes, dissolves the ordinary sense of self. Two companies have carried purified versions into hospital trials, and the results so far are unusually striking. In the only published trial that measured mood against a dummy treatment, most people with long-standing, treatment-resistant low mood were symptom-free within a day, while nobody in the comparison group was. A small open study in heavy drinkers pointed the same way. Field studies of people using it outside medicine report lasting gains in mood, calm, and satisfaction with life.

Against that sit real limits. The trials are small, short, and run almost entirely by the two firms that own them, and the experience is so unmistakable that nobody stays unaware of which group they are in. Sharp rises in blood pressure, nausea, and overwhelming fear during the session are common, and a large share later have sudden, unbidden returns of the state — usually welcome, sometimes not. One death is on record from swallowing it alongside plant material that blocks its breakdown. Secretion scraped from toads varies enormously in strength and carries heart-active chemicals that the purified compound does not.

What remains uncertain is how long the benefit lasts, how the compound behaves with repeated exposure, and how much of the present signal rests on data from parties who profit from it.

Top - Benefits - Risks - Protocol